Literature DB >> 27432820

Extra-adrenal induction of Cyp21a1 ameliorates systemic steroid metabolism in a mouse model of congenital adrenal hyperplasia.

Yasuhiro Naiki1, Mami Miyado, Reiko Horikawa, Noriyuki Katsumata, Masafumi Onodera, Songya Pang, Tsutomu Ogata, Maki Fukami.   

Abstract

Congenital adrenal hyperplasia (CAH) due to steroid 21-hydroxylase (21-OH) deficiency (21-OHD) is an autosomal recessive disorder, in which CYP21A2 mutations or deletions result in underproduction of glucocorticoid and mineralocorticoid, and overproduction of androgens. Patients with CAH are treated with oral steroid supplementation, but optimal control of blood steroid levels remains difficult. Thus, new therapeutic approaches are still needed. Previously, adenovirus-mediated administration of human CYP21A2 to adrenal glands rescued the phenotype of a mouse model of 21-OHD. In this study, we examined whether transduction of murine Cyp21a1 in extra-adrenal tissues could rescue steroid metabolism in 21-OHD mice. We transduced primary fibroblasts obtained from 21-OHD mice with a retroviral vector containing Cyp21a1. In vitro assays demonstrated that Cyp21a1-expressing fibroblasts can uptake progesterone from the culture media, convert it to deoxycorticosterone (DOC), and subsequently release DOC back into the media. Autotransplantation of Cyp21a1-expressing fibroblasts into the subcutaneous tissues of the back resulted in a significant reduction in the serum progesterone/DOC ratio in four of six 21-OHD mice at 4 weeks after injection. We also directly injected an adeno-associated viral vector containing Cyp21a1 into the thigh muscles of 21-OHD mice. Serum progesterone/DOC ratios were markedly reduced in all four animals at 4 weeks after injection. These results indicate that extra-adrenal induction of Cyp21a1 ameliorates steroid metabolism in 21-OHD mice. This study suggests a novel therapeutic strategy for congenital adrenal hyperplasia, which warrants further investigations.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27432820     DOI: 10.1507/endocrj.EJ16-0112

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  9 in total

1.  Response to Letter to the Editor: "Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline".

Authors:  Phyllis W Speiser; Richard J Auchus; Deborah P Merke; Walter L Miller; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2019-06-01       Impact factor: 5.958

2.  An AAVrh10-CAG-CYP21-HA vector allows persistent correction of 21-hydroxylase deficiency in a Cyp21-/- mouse model.

Authors:  M Perdomini; C Dos Santos; C Goumeaux; V Blouin; P Bougnères
Journal:  Gene Ther       Date:  2017-02-06       Impact factor: 5.250

3.  Transcriptomic analysis and plasma metabolomics in Aldh16a1-null mice reveals a potential role of ALDH16A1 in renal function.

Authors:  Georgia Charkoftaki; Ying Chen; Ming Han; Monica Sandoval; Xiaoqing Yu; Hongyu Zhao; David J Orlicky; David C Thompson; Vasilis Vasiliou
Journal:  Chem Biol Interact       Date:  2017-02-28       Impact factor: 5.192

Review 4.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

Review 5.  Management challenges and therapeutic advances in congenital adrenal hyperplasia.

Authors:  Ashwini Mallappa; Deborah P Merke
Journal:  Nat Rev Endocrinol       Date:  2022-04-11       Impact factor: 47.564

Review 6.  Emerging medical therapies for congenital adrenal hyperplasia.

Authors:  Phyllis W Speiser
Journal:  F1000Res       Date:  2019-04-02

Review 7.  Disorders of Sex Development of Adrenal Origin.

Authors:  Gabriela P Finkielstain; Ana Vieites; Ignacio Bergadá; Rodolfo A Rey
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-20       Impact factor: 5.555

Review 8.  Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia.

Authors:  Alessandro Prete; Richard J Auchus; Richard J Ross
Journal:  Eur J Endocrinol       Date:  2021-11-30       Impact factor: 6.664

Review 9.  Novel treatments for congenital adrenal hyperplasia.

Authors:  Mariska A M Schröder; Hedi L Claahsen-van der Grinten
Journal:  Rev Endocr Metab Disord       Date:  2022-02-23       Impact factor: 9.306

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.